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Available online 31 March 2016Despite the prevalence of migraine, the pathophysiology of the disease remains unclear. Current understanding
of migraine has alluded to the possibility of a hyperexcitable brain. The aim of the current study is to investigate
human brainmetabolite differences in the anterior cingulate cortex (ACC) during the interictal phase inmigraine
patients. We hypothesized that there may be differences in levels of excitatory neurotransmitters and/or their
derivatives in themigraine cohort in support of the theory of hyperexcitability in migraine. 2D J-resolved proton
magnetic resonance spectroscopy (1H-MRS) data were acquired on a 3 Tesla (3 T) MRI from a voxel placed over
the ACC of 32 migraine patients (MP; 23 females, 9 males, age 33 ± 9.6 years) and 33 healthy controls (HC; 25
females, 8 males, age 32 ± 9.6 years). Amplitude correlation matrices were constructed for each subject to eval-
uate metabolite discriminability. ProFit-estimated metabolite peak areas were normalized to a water reference
signal to assess subject differences. The initial analysis of variance (ANOVA) was performed to test for group dif-
ferences for all metabolites/creatine (Cre) ratios between healthy controls and migraineurs but showed no sta-
tistically signiﬁcant differences. In addition, we used a multivariate approach to distinguish migraineurs from
healthy subjects based on the metabolite/Cre ratio. A quadratic discriminant analysis (QDA) model was used
to identify 3 metabolite ratios sufﬁcient to minimize minimum classiﬁcation error (MCE). The 3 selectedmetab-
olite ratios were aspartate (Asp)/Cre, N-acetyl aspartate (NAA)/Cre, and glutamine (Gln)/Cre. These ﬁndings are
in support of a ‘complex’ of metabolite alterations, whichmay underlie changes in neuronal chemistry in themi-
graine brain. Furthermore, the parallel changes in the three-metabolite ‘complex’may confermore subtle but bi-
ological processes that are ongoing. The data also support the current theory that the migraine brain is
hyperexcitable even in the interictal state.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Central sensitization1. Introduction
Although the cause of migraine attacks remains unknown, a number
of studies have indicated that migraine alters brain structure and func-
tion, including behavioral studies (Borsook et al., 2014; Brigo et al.,in, Boston Children's Hospital, 1
(D. Borsook).
. This is an open access article under2013; Hoffken et al., 2009) and neuroimaging studies (Sprenger and
Borsook, 2012). An increasing number of studies have evaluated mea-
sures of brain chemistry in migraine patients (see below). Altered
chemistry inmigrainemay provide a basis for the purported cortical hy-
perexcitability (Coppola et al., 2007; Demarquay et al., 2013), and could
be a target for evaluating treatment efﬁcacy in responders and non-
responders, as has been reported in other chronic pain conditions
such as ﬁbromyalgia (Harris et al., 2013), or evaluation of the effects
of treatments (e.g., topiramate) on brain metabolites (Moore and
Wardrop, 2006).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Reyngoudt et al., 2012). These studies have consistently suggested al-
tered energy metabolism (Reyngoudt et al., 2011) in migraine patients
but few studies have reported alterations in glutamate (Glu) or
gamma aminobutyric acid (GABA) in migraine patients, the latter two
components providing a potential basis for hyperexcitability (either in-
creased Glu or decreased GABA or some combination that contributes to
potential neuronal hyperexcitability). A recent paper reported signiﬁ-
cantly increased GABA in migraine using a Mescher-Garwood point-
resolved spectroscopy (MEGA-PRESS) sequence (Aguila et al., 2015)
and higher glutamine (Gln)/glycine (Gly) ratios in women than in
men during their interictal phase of migraine (Gonzalez de la Aleja
et al., 2013), offering some support for the hyperexcitability thesis.
The hyperexcitability thesis relates to the sensitization that results
from cortical spreading depression (CSD). CSD has been implicated in
the pathogenesis of migraine but is still not fully understood. Studies
have indicated that the wave of activation and subsequent inhibition
caused by CSD results in the sensitization of the trigeminal vascular sys-
tem and its central projections (Cutrer and Charles, 2008). Others have
suggested that hyperexcitability of the trigeminovascular neurons may
stem from altered descendingmodulation of the brain stemwhich may
cause a loss of inhibition or enhanced facilitation (Moulton et al., 2008).
MRS studies have found evidence of this with increases in both excit-
atory (Gonzalez de la Aleja et al,. 2013) and inhibitory (Aguila et al.,
2015) neurotransmitters suggesting a potentially more complex
changes in brain neurochemistry that contributes to a hyperexcitable
state.
Here we have used an approach to optimize the measurements of
both GABA and Glu with a 2D J-resolved approach, focusing on the an-
terior cingulate cortex (ACC).Wehave chosen theACC because of its pu-
tative role in multiple processing in migraine including involvement in
salience (Borsook et al., 2013), descending modulation (Mainero et al.,
2011), and altered resting state connectivity (Russo et al., 2012;
Tessitore et al., 2015; Xue et al., 2013). Conventional proton MRS (1H-
MRS) is often hampered by low spectral resolution and metabolite
peak overlap, especially to measure GABA and Gln/Glu concentrations.
Reliable detection and quantization of metabolite concentrations is
thus problematic. Two-dimensional (2D) 1H-MRS methodologies effec-
tively increase spectral resolution by spreading metabolite resonances
over a 2D surface and accounting for J-coupling resonances.We hypoth-
esized that we would be able to determine measures of GABA and/or
Glu in migraine and healthy subjects and that differences between
two populations can be differentiated based on the chemical signature
as has been done in other pain states (Foerster et al., 2012; Niddam
et al., 2011) as well as acute pain (Cleve et al., 2015). We have previ-
ously shown that metabolites can differentiate healthy subjects from
migraine patients using a linear discriminate analysis (LDA) approach
(Prescot et al., 2009). Here in a larger patient population along with a
QDA analysis we hope to gain a more thorough understanding of how
metabolite concentrations (speciﬁcally GABA and Glu) differ and if the
differences are in support of the current theory of a hyperexcitable mi-
graine brain (Welch et al., 1990).
2. Methods
2.1. Subject selection
The local Institutional Review Board (IRB) of Partners Health Care
approved the present study protocol, which met the requirements for
investigations in human subjects. A total of 33 healthy control (HC; 25
females, 8 males, mean age= 32± 9.6 years) subjects and 32migraine
patients (MP; 23 females, 9males, mean age=33+9.6 years) were in-
cluded in this study. All subjects were between the ages of 18–50, right-
handed, non-smokers, and had no signiﬁcant history of other chronic
pain, psychiatric, neurological or any other major disorders. At the be-
ginning of each study visit, subjects were screened for depression(Beck Depression Inventory II (Beck et al., 1996), exclusionary
score N 25 [moderate to severe depression]) as well as a urine test for
barbiturates, benzodiazepines, amphetamine, cocaine, tetrahydrocan-
nabinol, phencyclidine and opioids (excluding prescription pain medi-
cations). Healthy controls were also excluded if they were on any
prescription medications or had any history of migraine. All migraine
subjects ﬁt the criteria for episodic migraine in accordance with the In-
ternational Classiﬁcation for Headache II and conﬁrmed by a neurolo-
gist. The migraine subjects also had to have had a history of migraine
for at least 3 years and were excluded if they were on any daily preven-
tative medications for their migraine. In order to conﬁrm the migraine
subjects were in the interictal phase, we asked if they had an attack
within 24 h leading to their study visit and then followed up with
them 72 h after the study visit. If subjects experienced an attack within
that window of time, they were disqualiﬁed.
2.2. 2D MRS data acquisition
All MR imaging and 2D J-resolved 1H MRS measurements were per-
formed using a 3 Tesla Siemens (Erlangen, Germany) TIM Trio™whole-
body MRI system housed at McLean Hospital (Belmont, MA). Radiofre-
quency (RF) excitation and signal reception was achieved using a
manufacturer-supplied circularly polarized body RF coil and a 12-
channel phased array receive-only RF coil (operated in the four-
cluster mode, 3 elements per cluster), respectively. Subjects were posi-
tioned supine and foam pads were utilized to ﬁxate the headwithin the
RF receive coil. Following the acquisition of low-resolution localizer MR
images, high-resolution 3D magnetization-prepared rapid gradient
echo (MP-RAGE; TR/TE/TI = 2000/3.53/1100 ms; FOV =
256 × 256 × 224 mm; isotropic 1 mm in-plane resolution) MRI data
then were acquired to facilitate accurate MRS voxel positioning and
for post hoc within-voxel tissue-type segmentation. All spectroscopy
data were acquired from a voxel (30 × 22 × 25mm3) positioned within
the anterior cingulate cortex (ACC), which was obliqued along the sag-
ittal plane and positioned to cover predominantly graymatter. B0 shim-
ming was performed over the MRS voxel using the manufacturer-
supplied phase map method as well as additional interactive manual
shimming until a full-width at half-maximum (FWHM) of ≤12 Hz was
observed for the real component of the unsuppressed water signal
line width. 2D J-resolved 1H MRS data were recorded using a modiﬁed
PRESS sequence as described in an earlier report (Prescot and
Renshaw, 2013). Brieﬂy, 2D MRS acquisition parameters were as fol-
lows: TR/TE = 2000/31–229 ms; ΔTE = 2 ms; 4 signal averages per
TE step; 2D spectral width = 2000 × 500 Hz; 2D matrix size =
2048 × 100 Hz; maximum echo sampling based on the echo center of
the ﬁrst echo (i.e. TE = 31 ms); total acquisition time = 28 min 18 s.
Outer-volume suppression and solvent water suppression were
achieved using manufacturer-supplied techniques as described else-
where (Prescot and Renshaw, 2013). Water unsuppressed 2D 1H MRS
data also were recorded from the ACC voxel using 2 signal averages
per TE step. The RF transmitter frequency was set relative to total ACC
(3.0 ppm) and tissue water (4.7 ppm) resonances for the water sup-
pressed and unsuppressed measurements, respectively.
2.3. Tissue segmentation
The BET (Smith, 2002) and FAST (Zhang et al., 2001) tools provided
with the freely-available FMRIB Software Library (FSL) (Smith et al.,
2004) were used to perform skull stripping and whole brain tissue seg-
mentation, respectively. For each subject dataset, home-written
MATLAB (version 2010b, The MathWorks, Natick, MA) functions then
were used to extract the obliqued ACC MRS voxel to obtain within-
voxel gray matter (GM), white matter (WM), and cerebrospinal ﬂuid
(CSF) tissue content for each subject. The GMpercentagewas calculated
as the ration to total brain matter (i.e. 100 × GM / [WM+ GM]).
Table 1
Clinical characteristics (including medication usage) for individual migraine subjects.
Subject
ID
Age Gender Disease
duration
years
Avg. migraine
days/month
Visual
aura
Medications for
migraine
M01 34 M 20 12 No Excedrin migraine
M02 32 M 15 2 No Tylenol, ibuprofen
M03 49 F 39 13 Yes Imitrex
M04 36 F 20 12 No Aspirin, tylenol,
ibuprofen
M05 34 F 14 14 Yes Excedrin
M06 24 F 8 6 Yes Tylenol, aleve,
rizatriptan
M07 22 F 7 10 No Tylenol, ibuprofen
M08 25 F 7 10 Yes Ibuprofen
M09 22 F 3 2 Yes + Acetaminophen
M10 32 F 21 2 Yes Ibuprofen
M11 48 F 23 2 No None
M12 31 F 3 13 No Aspirin, ibuprofen
M13 37 M 33 2 No None
M14 24 F 4 1 No Tylenol
M15 26 M 3 10 No None
M16 30 F 9 4 No Naratriptan
M17 50 F 30 3 Yes Sumatriptan,
ibuprofen
M18 50 F 15 4 Yes Imitrex, ibuprofen
M19 38 F 27 12 Yes Sumatriptan,
ibuprofen, aspirin
M20 38 F 12 2 No Imitrex, naproxen
M21 32 M 26 7 Yes Tylenol
M22 32 F 14 6 No None
M23 41 F 23 3 No Ibuprofen
M24 46 M 6 6 Yes Ibuprofen, tylenol
M25 19 F 5 1 Yes None
M26 18 M 10 6 No None
M27 21 M 15 3 No Ibuprofen
M28 45 F 30 4 Yes Ibuprofen,
excedrin
M29 29 M 12 3 No None
M30 23 F 10 5 No Acetaminophen
M31 22 F 3 14 Yes None
M32 39 F 6 6 Yes Excedrin
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2D 1H MRS data were stored as Siemens TWIX ﬁles and transferred
to a personal computer system for pre-processing using MATLAB
scripts. Recombination of the four receiver channels was performed
using a scaled square-root of sum-of-squares conjugate reconstruction
method for both water suppressed and unsuppressed data. For the me-
tabolite water suppressed data, eddy current distortions initially were
accounted for using an established time-domain method,(Klose, 1990)
where each TE step from a given 2D 1H MRS dataset was corrected
using the corresponding water unsuppressed data recorded at the
same TE. Following coil cluster combination and eddy current correc-
tion, the residual water signal was removed on a TE-by-TE basis using
a Hankel singular value decomposition (HSVD) routine. Finally, the
corrected and water ﬁltered metabolite data were reconstructed to
yield a 2D matrix characterized by 100 TE steps and 2048 complex
points, and reformatted to produce individual ﬁle types recorded for
analysis by the ProFit software. The ProFit algorithm was applied iden-
tically to all ACC 2D 1H MRS data as detailed in previous reports,
(Prescot andRenshaw, 2013; Schulte and Boesiger, 2006)where follow-
ing zero-ﬁlling of the 2D matrix to 200 points along the indirectly de-
tected dimension, 2D fast Fourier Transformation, and phase
correction and frequency realignment, the software ﬁtted the a basis
set of nineteen metabolites in fully automated fashion. The basis set
consisted of: total creatine (Cre), N-acetyl aspartate (NAA),
glycerophosphorylcholine (GPC), phosphorylcholine (PCh), alanine
(Ala), aspartate (Asp), γ-amino butyric acid (GABA), glucose (Glc),
Gln, Glu, glycine (Gly), glutathione (GSH), lactate (Lac), myoinositol
(Ins), N-acetyl aspartylglutamate (NAAG), phosphoethanolamine (PE),
taurine (Tau), scyllo-inositol (sI), and ascorbic acid (Asc). The Cremeth-
ylene (CH2) and methyl (CH3) protons were ﬁtted separately whereas
the separate GPC and PCh peaks ultimately were considered as a com-
posite resonance (Cho). The Cramer-Rao lower bound (CRLB) values re-
ported by ProFit were used for assessing ﬁnal metabolite ﬁt precision.
Metabolites with CRLB outputs of b20% are considered sufﬁcient. Any
CRLB values N20% were excluded from the analysis.
2.5. 2D MRS data statistical analysis
Analysis of variance (ANOVA) initially was performed using
OriginLab (OriginLab Corporation, Northampton, MA) to test for group
differences for all metabolite/Cre ratios between healthy controls and
migraineurs. In addition, we used a multivariate approach to classify
migraineurs from healthy subjects based on the ratio of all 19 metabo-
lites expressed as the ratio to Cre (features). A quadratic discriminant
analysis (QDA) model was used in a forward feature selection wrapper
method (Kohavi and John, 1997) as implemented in MATLAB, with the
dataset (33 healthy controls, 32 migraineurs) being randomly divided
into training (N = 49) and testing (N = 16) groups. The feature selec-
tion procedure uses the minimum classiﬁcation error (MCE) of the
learning algorithmQDA on each feature subset as the performance indi-
cator for each subset. The training set is used to select the features and
ﬁt the QDAmodel while the test set is used to evaluate the performance
of the selected feature. Each candidate feature subset is evaluated and
compared with the application of a stratiﬁed 10-fold cross-validation
of the training set. These steps were implemented in MATLAB using
the functions ‘cvpartition’, ‘sequentialfs’, and ‘crossval’, which are all
provided with the Statistics Toolbox™.
3. Results
3.1. Subjects
Clinical characteristics (including medication usage) for individual
migraine subjects are given in Table 1 and all migraine subjects were
matched with age-gender to controls.3.2. MRI/MRS
Fig. 1(a) shows tissue segmented axial and sagittal T1-weightedMRI
data obtained from a single MP subject, displaying the typical ACCMRS
voxel location used for the present study. Group analysis for within-
voxel tissue composition revealed no signiﬁcant differences between
GM expressed as the percentage of total brain matter (HC 62 ± 4%;
MP 60±8%, p=0.1), or CSF (HC 13±6%;MP 13±5%, p=0.6). A rep-
resentative 2D J-resolved 1H MRS dataset recorded from the same sub-
ject is presented in Fig. 1(b), displaying the raw 2D spectral data and its
estimated spectral ﬁt as determined using ProFit (see Figure legend for
more details). Statistical groupmean analysis failed to reveal signiﬁcant
differences for the Cre-normalized metabolite levels.3.3. Statistical analysis
Standard statistical analysis using ANOVA yielded no signiﬁcantme-
tabolite differences between the migraine and the healthy control
groups. The results of feature extractionwith cross-validation, however,
indicated that 3 metabolite ratios were sufﬁcient to minimize MCE. The
resulting MCE was 0.0625, which corresponds to 1 subject in the test
group and the 3 selected metabolite ratios were Asp/Cre, NAA/Cre,
and Gln/Cre. Fig. 2 displays where the classiﬁcation error is ﬁrst mini-
mized by increasing the number of features used for a cross-validation
test of the discrimination. For these metabolites, the mean CRLB values
were 13.8 ± 8.2% (HC) and 11.5 ± 4.3% (MP) for Asp, 0.8 ± 0.4% (HC)
and 0.7 ± 0.3% (MP) for NAA, and 10.7 ± 3.6% (HC) and 9.4 ± 3.2%
(MP) for Gln. No signiﬁcant group differences existed for any of the
Fig. 1. (a) Skull stripped T1-weighted MRI data recorded from a single MP subject demonstrating typical ACC MRS voxel positioning (red box) on axial (top panel) and sagittal (bottom
panel) image slices. (b) 2D J-resolved 1H MRS data recorded from the MRS voxel shown in (a). The raw 2D MRS data (real component) is shown in the top panel with the black box
depicting the region used for spectral ﬁtting. The resulting 2D ﬁt as calculated using ProFit is shown in the bottom panel and tentative signal assignments are provided. The color bars
to the right show contouring amplitudes and signal phase.
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6.26 × 10−5 ± 6.13 × 10−6; MP 6.31 × 10−5 ± 7.33 × 10−6; p= 0.7)
nor the Cre CRLB values (HC 0.84 ± 0.36%; MP 0.74 ± 0.17%; p =
0.14) were found to signiﬁcantly differ between the two groups. In ad-
dition, no signiﬁcant symptom correlations were found after running a
correlation coefﬁcient analysis across multiple co-factors (age, sex, fre-
quency, and aura).
4. Discussion
We report results on interictal measures of metabolites, reproduced
and expanded from our intial ﬁndings previously reported (PrescotFig. 2.Number of features selection: The graph displays the cross-validationminimum classiﬁc
the ﬁrst true minimumwith 3 selected features.et al., 2009) albeit using a different statistical technique and with a
larger cohort. Our ﬁndings indicated that three metabolite ratios were
sufﬁcient to minimize the minimum classiﬁcation error (MCE) which
is a measure of misclassiﬁcation of erroneous group allocation. The ap-
proach used thus differentiated the patient group from the healthy con-
trols at both a group and at a matched level. The analysis allows for the
determination of discrimination of two or more groups (e.g., migraine
vs. healthy) based on CRE-normalized levels of speciﬁc metabolites.
Themajor ﬁnding relates to Gln (involved in both Glu and GABAmetab-
olism) and the excitatory amino acid neurotransmitter Asp (see below).
Changes in NAA may relate to a measure of ongoing physiological pro-
cesses including neuronal osmoregulation and myelination (seeation error (CVMCE) as the number of selected features is increased. The CVMCE acquires
592 L. Becerra et al. / NeuroImage: Clinical 11 (2016) 588–594below). The metabolites Asp, NAA, and Gln as a group differentiate pa-
tients from controls but is not possible to state (with statistical signiﬁ-
cance) that they are either elevated or reduced compared to patients.
We can state that the average of these metabolites in patients were
smaller than in controls but did not achieve statistical signiﬁcance. In
addition, we report the metabolite ratios as a ‘complex’ in an effort to
not only understand what changes have occurred but also to attempt
an explanation of why, based on metabolite interaction.
4.1. The cingulate cortex, chemistry and migraine
As noted in the introductionwe chose the ACC as a target tomeasure
metabolic changes. We, and others, have observed functional and mor-
phometric changes in the cingulate in episodic migraine (Maleki et al.,
2012). As noted previously, the cingulate is involved in numerous pro-
cesses in migraine behaviors (see Devinsky for a review (Devinsky
et al., 1995)) such as interoception (Critchley et al., 2004), executive
function (Carter et al., 2000), salience (Goldstein et al., 2009), painmod-
ulation (Zhang et al., 2005), amongst others. Studies have noted
changes in many of these functions in migraineurs (Mainero et al.,
2011; Niddam et al., 2015; Tessitore et al., 2015). As Shyu and Vogt
have noted in their evaluation of cingulate sub-territory or region func-
tions (Vogt, 2005), these differences may relate to “modiﬁcations of cin-
gulate synapses (from repeated migraine attacks) appear to regulate
afferent signals that may be important to the transition from acute to
chronic pain conditions associated with persistent peripheral noxious stim-
ulation” (Shyu and Vogt, 2009).
Receptor architecture of the ACC has been reviewed (Palomero-
Gallagher et al., 2009). Furthermore in vivo receptor binding studies in
humans, using positron emission tomography, have reported a number
of receptors in the region including dopamine D2 or D1 (Olver et al.,
2010; Suhara et al., 2002), GABA and benzodiazepine (Oblak et al.,
2009) as well as Glu receptors (Zavitsanou et al., 2002). Evaluation of
metabolic changes, that include molecules that may act on some of
these receptors (e.g., GABA or Glu) in the cingulate have been reported
across a number of disease states, including generalized anxiety disor-
ders (Strawn et al., 2013), obsessive compulsive disorders (Brennan
et al., 2015), autism (Baruth et al., 2013), alcoholism (Cohen-Gilbert
et al., 2015) and healthy subjects (Kuhn et al., 2015).
4.2. 2D resolved measures deﬁne metabolites that allow for segregation of
patient vs. controls
In our prior report we found that in interictal migraineurs theremay
be alterations in excitatory amino acids in the cingulate cortex of
migraineurs compared with healthy controls (Prescot et al., 2009).
Thiswas a small studyof 10 patients and 10 controls. In this study 33pa-
tients and 32 healthy matched controls were evaluated. The results re-
ported here show that there were 3 metabolite ratio's - NAA/Cre, Asp/
Cre and Gln/Cre - that could provide a segregation of the disease vs.
heathy state:
NAA is widely distributed in the CNS in both neurons and glia
(Baslow, 2003). It is syntehsized from Asp and acetyl-coenzyme A in
neurons (Moffett et al., 2007). It serves in a number of putative roles in-
cluding being a potential marker for neuronal health asmeasured using
MRS techniques (Luyten and den Hollander, 1986). It may play a role in
CNSmetabolism, nitrogen balance, neuronal osmoregulation and axon-
glial signaling (Moffett et al., 2007). In the healthy brain, NAA is one of
the largest peaks in the acquired MRS spectrum. The ratio between
NAA versus total creatine (NAA/Cre), have been found to be clinically
useful, since the latter usually remains constant (Miller, 1991). Most
clinical studies using MRS have reported decreases in NAA levels
(e.g., ischemia (Berthet et al., 2014), stroke (Igarashi et al., 2015), mul-
tiple sclerosis (Aboul-Enein et al., 2010), traumatic brain injury
(Moffett et al., 2013). Impairments of energy metabolism decrease
NAA levels in the brain. Given NAA's main role in energy metabolismand a source of acetate for fatty acid and steroid synthesis in oligoden-
drocytes (Moffett et al., 2007), what could its putative role in migraine
be? The migraine brain has been proposed to be (1) hyperexcitable or
have alterations in migraine energetics due to potential mitochondrial
dysfunction. Consistent with these ﬁndings, 1H-MRS studies have eval-
uated metabolite ratios in cluster headache in the hypothalamus and
show that the NAA/Cre ratio is lower in patients with cluster headache
vs. chronic migraine or controls (Wang et al., 2006). As in the case of
other conditions, the decrease in NAA may correlate with progressive
changes in migraine, worsened with increasing frequency (Mohamed
et al., 2013) or chronicity (Lai et al., 2015). As reported for TBI, for exam-
ple, decreased NAAmay be associated with an impairment of acetyl co-
enzyme A dependent functions (viz., energy derivation, lipid synthesis,
and protein acetylation) (Vagnozzi et al., 2007).
Gln is a major metabolite of Glu, a principle excitatory neurotrans-
mitter in the brain (Albrecht et al., 2010). Gln on the other hand is syn-
thesized exclusively in glial cells from Glu and ammonia by the enzyme
glutamine synthetase as a means for the brain to protect itself against
excitotoxicity from excess Glu and ammonia (Suarez et al., 2002). Sub-
sequently, Gln is released back into the extracellular space, shuttled
back into neurons and converted to Glu by glutaminase. The Glu that
is regenerated may then go on to play a direct role in excitatory neuro-
transmission (Prescot et al., 2009). Cerebrospinal ﬂuid (CSF) Gln, Gly
and taurine (Tau) concentrations are elevated in migraineurs
(Rothrock et al., 1995) suggesting glurgic systems are likely to be altered
in the migraine brain. It has been postulated that increased brain Glu
leads to cortical hyperexcitability typical of migraine (Goadsby, 2005).
Asp is amajor excitatory amino acid in the nervous system. It acts on
n-methyl-d-asparatate (NMDA) receptors.Measures of Asp are not nor-
mally reported inMRS studies. Ourmethod has allowed for a more spe-
ciﬁc determination of metabolites rendering signals from metabolites
that could not previously be parsed out such as Asp. The amino acid is
also part of a metabolic pathway involved in making NAA (Bates et al.,
1996).
The ‘complex’ of metabolites is described as such to not only under-
stand individual changes in metabolite ratios but to also discuss the in-
teractions since our analysis detected a signiﬁcant difference as a group
of metabolites. All three of the above mentioned metabolites have been
suggested as eventual precursers of glutimate (Albrecht et al., 2010;
Clark et al., 2006).
4.3. Consistent results across studies
While alterations in metabolites were reported in our prior study in
a small sample of migraine patients, themethod used here is more sen-
sitive: Gln and NAAG (a molecule of NAA and covalently bonded Glu)
were the linear discriminants. Here we observed that Gln is again
noted as a differentiator and NAA (previously NAAG), and Asp, all re-
lated to each other metabolically. Thus, although a slightly different
method was employed, we ﬁnd somewhat consistent results. The con-
ﬁrmation of Gln is of particular interest since in this static evaluation
of metabolites, the changes may represent abnormalities in a pathway
related to both Glu and GABA synthesis.
4.4. Lack of GABA and glutamate changes
Althoughwe had surmised thatwe should be able to evalute Glu and
GABA, such changes have been hard to deﬁne in migraine (Bridge et al.,
2015) and other chronic pain conditions (Foerster et al., 2015). Evalua-
tion of changes during a migraine attack (ictally) compared with
interictal timepoints may be one issue. During a migraine, while the re-
lease of excitatory amino acids including Glu and Asp may be ongoing,
as noted above, the changes are at micro-molar levels in the synaptic
clefts. Such changes cannot be measured using MRS. However, what
we observed were changes in Gln – the storage system of Glu.
Interictally the alterations in this metabolite, synthesized in glial cells,
593L. Becerra et al. / NeuroImage: Clinical 11 (2016) 588–594may represent amajor abnormality inmigraine. For example, theremay
be amalfunctionwithGln transport into neurons. Themethod however,
does not evaluate dynamic changes in Glu and indeed could not mea-
sure micro-molar levels in the synaptic clefts. More novel methods
such as 13C spectroscopy are needed (Gruetter et al., 2003; Yen et al.,
2011). 13C spectroscopy is a method using an infusion of 13C labelled
glucose that then gets incorporated into cell cycle (i.e., CREB). This
method may allow for understanding how metabolic forces may be
skewed in conditions such as migraine by observing alterations in Gln
shufﬂing (de Graaf et al., 2003).
Unlike Glu and Glx, GABA does not have a major role in metabolism,
and as such, 1H-MRS-derived GABA levels may be more indicative of
neural activity (Muthukumaraswamy et al., 2009). If the brain were
functioning normally, then an increase in Glu (or Glu precursors)
would indicate an increase in GABA (Eichler and Meier 2008). Our re-
sults suggest the possibility of excess excitation from excess Glu but
no excess inhibition by excess GABA. The Glu to GABA balance is imper-
ative for normal neuronal activity and without it may ultimately lead to
a hyperexcitable brain.
5. Caveats
5.1. Sensitivity
The method reported here allows for an improved spectral analysis.
However, there are issues with spectroscopy including acquisition
(e.g., movement, shimming standards) or voxel location in the brain.
In this sample there was b1 mm movement and the voxel placement
was always performed in a routinemanner by the same individual. Var-
iances of concentration measures may also be present (van de Bank
et al., 2015).
5.2. Metabolite-to-creatine ratios
Although metabolite ratios are commonly used to report changes
(Lirng et al., 2015), determining absolute concentrations is also becom-
ing a usual approach. Bothmethods have advantages and disadvantages
including factors affecting water quantiﬁcation (Hernandez-Tamames
et al., 2016) or scanning parameters and models (Yamamoto et al.,
2015). Furthermore, pathological changes may affect metabolic ratios
(Cheong et al., 2006). Potential utilization of absolute quantiﬁcation in
the clinical setting might require additional resources and expertise
not easily available and metabolite ratios might be a solution to assess
changes in brain chemistry.
5.3. Patient phenotype
In this cohort patients were recruited primarily for the frequency of
migraine. Thuswehave a group of patientswith high and low frequency
attacks (i.e., episodic migraine). Some patients also had auras. Our anal-
ysis did not show any differences when these and other variables (in-
cluding sex or age) were evaluated.
5.4. Medications
As noted in our patient inlcusion criteria (see Methods), patients re-
cruited were taking only either NSAIDS, triptans or both. Drugs includ-
ing NSAIDS may alter chemisty directly and thus may confound or
contribute to the observed changes.
6. Conclusion
Our results indicate changes in certain metabolites in migraineurs
compared to controls. Our results also replicate and further validate a
previous, smaller study (Prescot et al., 2009). They also extendmetabo-
lites to differentiate patients from controls including now NAA, Gln andaspartate. Understanding the biochemical alterations in the brains of
migraine patients may allow for targeted new therapeutic approaches
of treatment as well as an approach to better understanding of the ef-
fects of medications on the brain.
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